Researchers in the Atopic Dermatitis Research Network (ADRN), will seek to better understand why atopic dermatitis patients are susceptible to staph and other bacterial and viral infections. They will evaluate atopic dermatitis patients' genes, innate and adaptive immune responses and skin barrier to identify factors that make them susceptible to these infections. The researchers also plan to conduct a clinical trial to see if vitamin D can help reduce or prevent staph colonization and infection.Researchers will be recruiting large numbers of atopic dermatitis patients to take part in clinical studies over the next five years. If you are interested in learning more about the Atopic Dermatitis Research Network, please call 1-888-413-5852.
Staph infections, however, are not the only potentially hazardous infections associated with atopic dermatitis. Atopic dermatitis patients are also susceptible to herpes virus infections, called eczema herpeticum, and a hazardous, potentially deadly side effect of smallpox vaccinations, eczema vaccinatum, which occurs when the vaccinia virus currently used for the smallpox vaccine, replicates uncontrollably and circulates through the entire body.
The ADRN research consortium is building on a previous five-year contract, which created the Atopic Dermatitis Vaccinia Network and identified several factors related to patients' susceptibility to eczema vaccinatum.
The Atopic Dermatitis Research Network will include researchers from National Jewish Health, Emory University, Boston Children's Hospital, Johns Hopkins University, University of Rochester, Oregon Health and Sciences University, La Jo
|Contact: William Allstetter|
National Jewish Health